AEB071
AEB071 is a pharmaceutical drug with 15 clinical trials. Historical success rate of 80.0%.
Success Metrics
Based on 12 completed trials
Phase Distribution
Phase Distribution
10
Early Stage
5
Mid Stage
0
Late Stage
Highest Phase Reached
Phase 2Trial Status & Enrollment
80.0%
12 of 15 finished
20.0%
3 ended early
0
trials recruiting
15
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
Clinical Trials (15)
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation
A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis
Efficacy, Safety and Tolerability of AEB071 in Patients With Active, Moderate to Severe Ulcerative Colitis
Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis
Study of AEB071 (a Protein Kinase C Inhibitor) in Patients With CD79-mutant Diffuse Large B-Cell Lymphoma
Safety and Efficacy of AEB071 in Metastatic Uveal Melanoma Patients
Safety and Efficacy of AEB071 and EVEROLIMUS in Patients With CD79-mutant or ABC Subtype Diffuse Large B-Cell Lymphoma
24 Month Extension to Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients(Converted to Mycophenolic Acid After 3 Months) in Renal Transplant Patients
Efficacy and Safety of AEB071 Plus Tacrolimus (Converted to Mycophenolic Acid After 3 Months), in Renal Transplant Patients
Pharmacokinetic Study of AEB071 in Patients Following Liver Transplantation
A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma
Efficacy, Safety and Tolerability of AEB071 Versus Cyclosporine in the Novo Renal Transplant Recipients
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of AEB071
Safety of AEB071 in Healthy Volunteers and to Compare the Ethnicity, Metabolic, and Safety Effects Between Caucasian and Japanese Healthy Subjects
All 15 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 15